On Dec. 11, 2020, Eli Lilly and Incyte announced The New England Journal of Medicine had published the peer-reviewed results from the Adaptive COVID-19 treatment trial (ACTT-2) sponsored by the NIAID.

The Phase 3 study included 1,033 patients from 67 trial sites in eight countries. These results supported the emergency use authorization (EUA) issued by the FDA on Nov. 19 for baricitinib in combination with remdesivir in hospitalized patients with COVID-19 requiring supplemental oxygen.